Qiagen, Illumina to deliver NGS-based IVD kits

Create PDF

“We are committed to expanding the range of clinical use cases addressed by genomic sequencing by enabling partners to deliver IVD tests and companion diagnostics on Illumina’s Dx instruments,” Francis deSouza, CEO of Illumina, said in a company press release. “Our partnership with Qiagen will complement Illumina’s TSO 500 family with additional testing menu options, accelerating NGS adoption in oncology patient management.”

The partnership will initially focus on commercializing oncology IVD kits and may expand to include additional clinical diagnostic fields, such as cardiology, hereditary diseases, infectious diseases, and inflammatory and autoimmune diseases.